ukcitymedia news feed

Terms of Indivior PLC disinvestment of 'Sai Bo Song' tablets in China announced

Terms of Indivior PLC disinvestment of 'Sai Bo Song' tablets in China announced

Mon 4 Feb 2019 07:51 by ukcitymedia.co.uk about : operational news - 0 Comments - 506 words


Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that it has entered into a definitive agreement to divest its rights related to the Sai Bo Song™ (buprenorphine, naloxone) tablet in China to Zhejiang Pukang Biotechnology Co., Ltd. ("Pukang") for a total consideration of up to $122.5 million

Pukang is a privately held company focused on vaccines and headquartered in Hangzhou, China that is seeking to diversify into small molecule therapies.

"The divestiture of the Sai Bo Song™ tablet in China is consistent with Indivior's efforts to prioritize efforts on the long-term growth opportunities with our new depot assets, SUBLOCADE™ and PERSERIS™," said Shaun Thaxter, Chief Executive Officer of Indivior. "This transaction helps us focus our resources on the highest return opportunities in the regions we know best, while ensuring patients in China have access to an important and transformational treatment."

Thaxter continued, "With its knowledge of the local environment and scientific heritage, we believe Pukang is well suited to advance the science of addiction treatment in China."

Terms of the Transaction

The transaction is subject to the designation of the Sai Bo Song™ tablet as a Class II psychotropic drug by Chinese regulators, Chinese outbound investment approvals, and other closing conditions.

The foregoing regulatory hurdles will occur throughout 2019 and the transaction is targeted to close by end of Q4, 2019.

Terms of the transaction include a signing payment of $1.5 million, $3.5 million upon designation of the Sai Bo Song™ tablet as a Class II psychotropic drug by Chinese regulators, and $12.5 million upon closing of the transaction, for a total of $17.5 million in near-term payments. Indivior may receive an additional $105.0 million based on certain technical assistance to be provided by Indivior to Pukang and the achievement of certain sales milestones during a ten-year period following the first commercial sale of the product in China, for a total consideration of up to $122.5 million.



These articles are summaries / highlights and dont always include all financial news updates. Check at company website INVESTORS INFORMATION for full published results.


Add a comment


Username:


Email:


Security key:


Message:






More

ukcitymedia news feed

Please take our RSS Feed and news to your Network and message boards. With thanks





 


ukcitymedia moderates but does not authenicate postings. Users are reminded that shares and all trading instruments by nature do not always prove to be good investments. Readers are reminded to do your own research. ukcitymedia.co.uk delivers UK stock market news, latest shares news, uk financial news, rns news articles, latest business news, latest uk financial news, stockmarket investment news, business news round-ups. director dealings bulletins, stock market reports, share trading articles, latest finance news, broker recommendations, uk city news, latest financial information. ukcitymedia.co.uk does not offer financial advice.